RhumbLine Advisers
ALDX icon

RhumbLine Advisers’s Aldeyra Therapeutics ALDX Stock Holding History

RhumbLine Advisers’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.8K Sell
26,652
-42,553
-61% -$73.1K ﹤0.01% 3658
2026
Q1 		$117K Sell
69,205
-1,208
-2% -$5.29K ﹤0.01% 3342
2025
Q4 		$365K Sell
70,413
-8,233
-10% -$42.3K ﹤0.01% 2862
2025
Q3 		$411K Buy
78,646
+1,152
+1% +$6.01K ﹤0.01% 2823
2025
Q2 		$297K Buy
77,494
+2,018
+3% +$5.22K ﹤0.01% 2991
2025
Q1 		$434K Sell
75,476
-2,712
-3% -$16K ﹤0.01% 2661
2024
Q4 		$390K Buy
78,188
+1,087
+1% +$5.58K ﹤0.01% 2825
2024
Q3 		$416K Buy
77,101
+120
+0.2% +$571 ﹤0.01% 2831
2024
Q2 		$255K Buy
76,981
+12,907
+20% +$50.5K ﹤0.01% 3089
2024
Q1 		$210K Buy
64,074
+2,211
+4% +$7.27K ﹤0.01% 3153
2023
Q4 		$217K Sell
61,863
-649
-1% -$2K ﹤0.01% 3147
2023
Q3 		$418K Buy
62,512
+3,018
+5% +$22.4K ﹤0.01% 2718
2023
Q2 		$499K Buy
+59,494
New +$586K ﹤0.01% 2685
2022
Q2 		– Sell
-47,596
Closed -$212K – 3092
2022
Q1 		$212K Buy
47,596
+4,996
+12% +$19.9K ﹤0.01% 2741
2021
Q4 		$170K Sell
42,600
-853
-2% -$6.51K ﹤0.01% 2868
2021
Q3 		$382K Buy
43,453
+1,923
+5% +$17.6K ﹤0.01% 2672
2021
Q2 		$471K Buy
+41,530
New +$499K ﹤0.01% 2589
2020
Q2 		– Sell
-30,784
Closed -$76K – 3061
2020
Q1 		$76K Hold
30,784
– – ﹤0.01% 2823
2019
Q4 		$179K Buy
30,784
+143
+0.5% +$826 ﹤0.01% 2779
2019
Q3 		$161K Buy
30,641
+706
+2% +$3.8K ﹤0.01% 2799
2019
Q2 		$180K Buy
29,935
+2,752
+10% +$20.7K ﹤0.01% 2817
2019
Q1 		$245K Buy
27,183
+4,010
+17% +$34.1K ﹤0.01% 2652
2018
Q4 		$192K Buy
23,173
+9,260
+67% +$94.9K ﹤0.01% 2748
2018
Q3 		$192K Sell
13,913
-343
-2% -$2.78K ﹤0.01% 2738
2018
Q2 		$113K Buy
+14,256
New +$114K ﹤0.01% 2859

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

RhumbLine Advisers's ALDX Position: Q2 2026 in Review

RhumbLine Advisers reduced its Aldeyra Therapeutics (ALDX) stake by 61% in Q2 2026, selling an estimated $73.1K and leaving 26,652 shares worth $56.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3658.

RhumbLine Advisers first reported a position in ALDX in Q2 2018 and has held it in 25 quarters since. The position peaked at $499K in Q2 2023. 107 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • RhumbLine Advisers held 26,652 shares of Aldeyra Therapeutics worth $56.8K as of Q2 2026.
  • RhumbLine Advisers sold 42,553 Aldeyra Therapeutics shares in Q2 2026, an estimated $73.1K.
  • Aldeyra Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3658 holding.
  • RhumbLine Advisers first reported a position in Aldeyra Therapeutics in Q2 2018 and has held it in 25 quarters since.
  • RhumbLine Advisers's Aldeyra Therapeutics position peaked at $499K in Q2 2023.
  • 107 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.